Global Catheter-Related Bloodstream Infections Market to Reach US$1.9 Billion by 2030

The global market for Catheter-Related Bloodstream Infections estimated at US$1.5 Billion in the year 2024, is expected to reach US$1.9 Billion by 2030, growing at a CAGR of 4.0% over the analysis period 2024-2030. Anti-Microbial Agents, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Antibiotic Lock Therapy segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$398.9 Million While China is Forecast to Grow at 7.5% CAGR

The Catheter-Related Bloodstream Infections market in the U.S. is estimated at US$398.9 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$380.0 Million by the year 2030 trailing a CAGR of 7.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR.

Global Catheter-Related Bloodstream Infections (CRBSIs) Market – Key Trends & Drivers Summarized

Why Are Catheter-Related Bloodstream Infections a Persistent Challenge in Critical Care and Hospital Infection Control?
Catheter-related bloodstream infections (CRBSIs) remain a significant cause of morbidity, mortality, and increased healthcare costs in clinical settings—particularly in intensive care units, oncology wards, and long-term care facilities. These infections arise when pathogens colonize intravascular catheters, leading to systemic bloodstream infections that complicate treatment outcomes and extend hospital stays. As central venous catheters (CVCs) are widely used for medication administration, parenteral nutrition, and hemodynamic monitoring, CRBSIs represent a serious nosocomial risk that continues to strain hospital infection control protocols.

Despite improved awareness, the global burden of CRBSIs persists due to inconsistent adherence to aseptic insertion techniques, prolonged catheter dwell times, and antimicrobial resistance. The need to minimize preventable infections is intensifying as healthcare systems prioritize quality metrics, patient safety, and cost containment—driving sustained demand for advanced prevention tools, diagnostics, and bundled care solutions targeting CRBSIs.

How Are Innovations in Catheter Materials, Antimicrobial Coatings, and Infection Surveillance Improving CRBSI Prevention?
Medical device manufacturers are advancing catheter technologies through the use of antimicrobial and antiseptic coatings (e.g., silver sulfadiazine, chlorhexidine, and minocycline-rifampin) that inhibit microbial adhesion and biofilm formation. These coated catheters are increasingly adopted in high-risk settings to reduce infection rates without compromising vascular access functionality. Improvements in catheter insertion kits, securement devices, and transparent dressings are further enhancing infection barrier protection.

Electronic health record (EHR)-linked infection surveillance systems and real-time analytics platforms are also supporting early detection and tracking of CRBSIs. Standardized central line bundles, clinical decision support tools, and nurse-driven removal protocols are being implemented to drive compliance and accountability in line care. Additionally, point-of-care diagnostic tools and rapid culture systems are aiding timely pathogen identification and targeted antibiotic administration, improving patient outcomes.

Where Is Demand for CRBSI Prevention and Management Solutions Growing and Which Clinical Environments Are Driving Adoption?
North America leads global CRBSI prevention efforts, supported by well-established hospital quality reporting frameworks and stringent CMS and CDC guidelines. The U.S. continues to drive demand for coated catheters, diagnostic tests, and infection surveillance software. Europe follows with increasing adoption of catheter care bundles and region-wide patient safety initiatives. Asia-Pacific is witnessing strong growth in infection control markets, particularly in countries like India, China, and Japan, where expanding ICU infrastructure and rising surgical volumes are heightening CRBSI prevention priorities.

Key clinical environments include intensive care units, oncology departments, dialysis centers, and long-term acute care hospitals—settings where central venous access is common and patient vulnerability is high. Additionally, home infusion therapy and ambulatory care services are expanding the scope of CRBSI risk management beyond hospital walls, driving demand for portable infection prevention solutions and patient education tools.

What Is Fueling the Global Growth of the Catheter-Related Bloodstream Infections Market?
The global CRBSIs market is being driven by the rising use of vascular access devices, growing awareness of hospital-acquired infections (HAIs), and regulatory pressure to meet infection control benchmarks. As healthcare providers focus on reducing preventable harm and optimizing clinical outcomes, investment is increasing in bundled solutions that combine coated catheters, securement systems, and staff training protocols. The financial burden of CRBSIs—through increased treatment costs, penalties, and reputational risk—continues to reinforce the strategic imperative for effective prevention.

Innovation in catheter materials, AI-enabled infection tracking, and targeted antimicrobial therapies is accelerating product development and adoption. Strategic collaborations between device manufacturers, infection control teams, and health IT vendors are enabling more integrated, data-driven CRBSI mitigation strategies. As global health systems strive to eliminate catheter-associated complications, a defining question frames the path forward: Can CRBSI prevention evolve into a standardized, evidence-based, and technology-augmented framework—while ensuring cost-effectiveness, scalability, and patient safety across varied care delivery environments?